THURSDAY, June 6, 2024 (HealthDay News) — A popular smoking cessation aid is equally effective for people with and without a history of mental illness, according to a study published online June 4. PLOS Mental Health.
Dr. Sarah E. Jackson of University College London and colleagues investigated whether the actual effectiveness of a popular smoking cessation aid differs for users with and without a history of mental illness. The analysis included 5,593 adults (2,524 with a history of at least one mental illness) who smoked regularly within the past year and had made at least one quit attempt within the past year.
The researchers found that participants with a history of psychiatric illness were significantly more likely to report using e-cigarette products (30.7% vs. 38.8% of participants without psychiatric illness), prescription nicotine replacement therapy (2.7% vs. 4.8%), and websites (2.2% vs. 4.0%). After adjusting for covariates and use of other smoking cessation aids, those who used e-cigarette products (odds ratio[OR]0.018-0.025) were more likely to report using e-cigarette products (3.2% vs. 0.018-0.025). [OR]Those who used either nicotine (OR, 1.92), varenicline (OR, 1.88), or heated tobacco products (OR, 2.33) were significantly more likely to quit smoking compared with those who reported no use of these adjuncts.
“In conclusion, after controlling for the use of other smoking cessation aids and potential confounding factors, we found that the use of e-cigarette products, varenicline, and heated tobacco products during a quit attempt was associated with significantly higher rates of cessation success,” the authors wrote. “There was no evidence that the effectiveness of common smoking cessation aids differed depending on the user’s history of psychiatric illness.”
Two of the authors revealed ties to Pfizer and Johnson & Johnson, which make smoking cessation drugs.
Abstract/Full text
Copyright © 2024 HealthDay. All rights reserved.
